Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma

[1]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[2]  A. Cochran,et al.  The role of practising pathologists in the generation of novel and original observations , 2001, The Journal of pathology.

[3]  J. Inazawa,et al.  Detection of chromosomal aneusomy by fluorescence in situ hybridization in fine‐needle aspirates from breast tumors , 2000, Cancer.

[4]  J. Eyfjörd,et al.  p53 abnormality and chromosomal instability in the same breast tumor cells. , 2000, Cancer genetics and cytogenetics.

[5]  M. Mottolese,et al.  Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. , 2000, Journal of the American College of Surgeons.

[6]  K. Grigor,et al.  Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder , 2000, BJU international.

[7]  Written on behalf of the Biomarkers Ad-hoc Group of the Un Research.  Can biological markers improve the management of breast cancer patients? , 2000 .

[8]  M. Dowsett,et al.  Assessment of HER2 status in breast cancer: why, when and how? , 2000, European journal of cancer.

[9]  E. Schröck,et al.  Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.

[10]  F. Mertens,et al.  Multiple polysomies in breast carcinomas: preferential gain of chromosomes 1, 5, 6, 7, 12, 16, 17, 18, and 19. , 1999, Cancer genetics and cytogenetics.

[11]  P. Maxwell,et al.  Interphase cytogenetics of chromosomes 11 and 17 in fine needle aspirates of breast cancer. , 1999, Human pathology.

[12]  K. Grigor,et al.  Is Chromosome 9 Loss a Marker of Disease Recurrence in Transitional Cell Carcinoma of the Urinary Bladder , 1999 .

[13]  A. Børresen-Dale,et al.  Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. , 1998, Cancer research.

[14]  市川 大輔.  Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer , 1998 .

[15]  D. Dillon,et al.  The molecular biology of breast cancer: accelerating clinical applications. , 1998, Critical reviews in oncogenesis.

[16]  J. R. Reeves,et al.  Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[18]  I. Ellis,et al.  Prognostic factors in primary breast carcinoma. , 1995, Journal of clinical pathology.

[19]  C. Herrington,et al.  Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes , 1995, The Journal of pathology.

[20]  E. Mallon,et al.  Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ , 1995, International journal of cancer.

[21]  S. Wolman.  Fluorescence in situ hybridization: a new tool for the pathologist. , 1994, Human pathology.

[22]  D. Visscher,et al.  Chromosomal aneuploidy in proliferative breast disease. , 1994, Human pathology.